Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil.
Publication
, Journal Article
Diehl, LF; Perry, DJ; Tang, DB
Published in: J Clin Oncol
October 1983
Duke Scholars
Published In
J Clin Oncol
DOI
ISSN
0732-183X
Publication Date
October 1983
Volume
1
Issue
10
Start / End Page
663 / 664
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Methotrexate
- Humans
- Fluorouracil
- Female
- Cyclophosphamide
- Breast Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Diehl, L. F., Perry, D. J., & Tang, D. B. (1983). Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol, 1(10), 663–664. https://doi.org/10.1200/JCO.1983.1.10.663
Diehl, L. F., D. J. Perry, and D. B. Tang. “Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil.” J Clin Oncol 1, no. 10 (October 1983): 663–64. https://doi.org/10.1200/JCO.1983.1.10.663.
Diehl LF, Perry DJ, Tang DB. Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1983 Oct;1(10):663–4.
Diehl, L. F., et al. “Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil.” J Clin Oncol, vol. 1, no. 10, Oct. 1983, pp. 663–64. Pubmed, doi:10.1200/JCO.1983.1.10.663.
Diehl LF, Perry DJ, Tang DB. Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1983 Oct;1(10):663–664.
Published In
J Clin Oncol
DOI
ISSN
0732-183X
Publication Date
October 1983
Volume
1
Issue
10
Start / End Page
663 / 664
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Methotrexate
- Humans
- Fluorouracil
- Female
- Cyclophosphamide
- Breast Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis